Circulating Nesfatin-1 Levels and Type 2 Diabetes: A Systematic Review and Meta-Analysis

Table 1

Characteristics of studies included in the meta-analysis.

Study	Region	Study type	Sample	Methods	T2DM criteria	Antidiabetic treatment	Duration	Sample size (M/F)		Nesfatin-1(μg/l)
								Case	Control	Case	Control
Algul et al. [10]	Turkey	Cross-sectional	Serum	ELISA	ADA	Yes	—	20 (−/−)	20 (−/−)	0.867 ± 0.09	1.094 ± 0.31
Dai et al. [11]	China	Cross-sectional	Serum	ELISA	ADA	Yes	—	55 (29/26)	48 (23/25)	1.26 ± 0.319	1.51 ± 0.467
Guo et al. [8]	China	Case-control	Plasma	ELISA	WHO	No	—	64 (34/30)	63 (31/32)	2.01 ± 0.64	1.35 ± 0.43
Li et al. [12]	China	Case-control	Plasma	ELISA	ADA	Yes	6.44 ± 0.91	47 (23/24)	20 (13/7)	0.99 ± 0.55	1.48 ± 0.72
Liu et al. [13]	China	Case-control	Plasma	ELISA	WHO	Yes	9.03 ± 3.48	30 (16/14)	30 (14/16)	0.73 ± 0.14	1.00 ± 0.23
Tang et al. [14]	China	Case-control	Serum	ELISA	WHO	Yes	4.56 ± 1.73	38 (18/20)	40 (21/19)	0.86 ± 0.42	1.1 ± 0.34
Zhang et al. [9]	China	Cross-sectional	Plasma	ELISA	WHO	No	—	74 (39/35)	73 (36/37)	1.91 ± 0.79	1.41 ± 0.58

ADA: American Diabetes Association; WHO: World Health Organization; —: not available or not reported. Data are presented as mean ± SD.